Figure 4.

Serum and tissue drug levels in human immunodeficiency virus type 1 (HIV-1)–infected peripheral blood lymphocyte (PBL)–NSG mice treated with 2 weekly injections of nanoformulated antiretroviral therapy (nanoART) combinations (atazanavir [ATV] and ritonavir [RTV] or ATV, RTV, and efavirenz [EFV]). Following subcutaneous injections of either ATV and RTV (H3001 and H2001; 250 mg/kg each) or ATV, RTV, and EFV (H3001, H2001, and H4001; 100 mg/kg each) given on days 0 and 7 to PBL-reconstituted, HIV-1–infected mice, drug levels of ATV, RTV, and EFV were determined in serum on days 1, 6 and 14 (A), and in liver, spleen, kidney, lung, and brain on day 14 (B). Data are expressed as median ± 25th (serum) and 75th (serum and tissues) percentiles for 8 mice per group.